Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes.
Albarracin, Cesar A. 1; Fuqua, Burcham C. 2; Evans, Joseph L. 3; Goldfine, Ira D. 4,*
[Article]
Diabetes/Metabolism: Research & Reviews.
24(1):41-51, January 2008.
(Format: HTML, PDF)
Background: Chromium and biotin play essential roles in regulating carbohydrate metabolism. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the combination of chromium picolinate and biotin on glycaemic control.
Methods: Four hundred and forty-seven subjects with poorly controlled type 2 diabetes (HbA1c >= 7.0%) were enrolled and received either chromium picolinate (600 [mu]g Cr 3) with biotin (2 mg), or matching placebo, for 90 days in combination with stable oral anti-diabetic agents (OADs). Major endpoints were reductions in HbA1c, fasting glucose, and lipids. Safety and tolerability were assessed.
Results: Change in HbA1c was significantly different between treatment groups (p = 0.03). HbA1c in the chromium picolinate/biotin group decreased 0.54%. The decrease in HbA1c was most pronounced in chromium picolinate/biotin subjects whose baseline HbA1c >= 10%, and highly significant when compared with placebo (-1.76% vs - 0.68%; p = 0.005). Fasting glucose levels were reduced in the entire chromium picolinate/biotin group versus placebo (-9.8 mg/dL vs 0.7 mg/dL; p = 0.02). Reductions in fasting glucose were also most marked in those subjects whose baseline HbA1c >= 10.0%, and significant when compared to placebo (-35.8 mg/dL vs. 16.2 mg/dL; p = 0.01). Treatment was well tolerated with no adverse effects dissimilar from placebo.
Conclusions: These results suggest that the chromium picolinate/biotin combination, administered as an adjuvant to current prescription anti-diabetic medication, can improve glycaemic control in overweight to obese individuals with type 2 diabetes; especially those patients with poor glycaemic control on oral therapy. Copyright (C) 2007 John Wiley & Sons, Ltd.
Copyright (C) 2008 John Wiley & Sons, Inc.